Salus Bioceutical Thailand (SBT) announced the establishment of high capacity cannabis and hemp manufacturing and extraction laboratory in Asia to meet the growing international and regional demand
SBT partners with Salus International Management Ltd. (SIM), a partially-owned subsidiary of MPX International Corporation (MPXI), a multinational diversified cannabis company for the project. According to SBT, the cannabis/hemp production plant is built at a cost of US$17.9mn in the Doi Saket district, Chiang Mai province, Thailand.
The company’s newly established facilities correspond to the demand for Cannabidiol (CBD) and Tetrahydrocannabinol (THC). The facility is expected to have an annual capacity for the extraction of over 200,000 kgs of biomass, production of over 50,000 l of CBD oil, 90,000 kgs of isolate powder and water-soluble CBD isolate, making SBT one of the largest cannabis/hemp manufacturing plants in Thailand and outside North America according to the Bangkok Post.
The 800 sq m production plant is said to house the indoor cultivation and a building facility for high capacity extraction and distillation which employs required equipment. The facility also features a medical-grade laboratory for hemp and cannabis analysis for the distillation process, used to produce high-yield and quality CBD products.
SBT is one of the first licenced CBD manufacturers from Thailand, after being granted the required ‘Hemp Extraction License’, to operate and extract hemp flower legally under the laws of Thailand.
Tanadee Pantumkomon, chief executive officer and director, SBT spoke to the Bangkok Post, “We are excited to be taking our first big step in Thailand. The opening of our local CBD manufacturing plant will enable us to better respond to the growing demand for a wide variety of CBD products both in Thailand and worldwide. The facility will create a value chain upstream to downstream as well as providing benefits for all stakeholders – including job opportunities and additional income for local communities.”